Conditions: Malaria
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 181
Healthy volunteers: no

Brief summary:
This is a study assessing safety and efficacy of current national guidelines for the treatment of uncomplicated malaria in Bangladesh as well as to assess the G6PD status among the enrolled patients.

Detailed description:
The national guidelines for the treatment of uncomplicated malaria in Bangladesh currently recommend a standard dose of artemether-lumefantrine followed by a single dose of primaquine for P. falciparum malaria and a three day course of chloroquine followed by 14 days of primaquine for vivax malaria.Currently the national treatment guidelines do not include any testing for G6PD deficiency before treatment with primaquine. In order to guarantee safe and efficacious treatment for all patients diagnosed with uncomplicated malaria in Bangladesh, it is essential to monitor the effectiveness and safety of the recommended treatment guidelines. This trial therefore evaluates the local efficacy and safety of the current first line treatment and assesses the G6PD status of the enrolled patients.

Patients with uncomplicated malaria attending the health care center, who meet the study inclusion criteria will be enrolled, treated on site and followed up for 28 days. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and laboratory examinations. The study will provide efficacy data for both artemether-lumefantrine and chloroquine and will generate data on G6PD status in the region, which will provide vital information for policy makers in regards to the wider roll out of primaquine for the radical cure of vivax malaria.

Arms:
arm 1: P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines arm 2: P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines arm 3: mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines

Interventions: intervention 1: chloroquine intervention 2: Artemether-lumefantrine combination intervention 3: Primaquine intervention 4: Primaquine
Intervention descriptions: intervention 1: standard dose intervention 2: standard dose intervention 3: single dose intervention 4: 14 days

Protocol document: